Renal Outcomes in GLP-1 Receptor Agonist Trials: Clinical Evidence Review

GLP-1 receptor agonist therapy lowers blood glucose and body weight, and landmark trials such as the FLOW study show these medications also slow the progression of chronic kidney disease. Renal outcomes now rank among the most clinically significant findings from GLP-1 receptor agonist trials. For patients with chronic kidney disease considering a physician-supervised GLP-1 weight-loss program at Age Well ATL in Atlanta, this kidney evidence belongs at the center of the treatment conversation.

How do GLP-1 receptor agonists work, and why would they affect kidney function?

GLP-1 receptor agonist therapy mimics the incretin hormone GLP-1, enhancing insulin secretion, suppressing glucagon, and slowing gastric emptying. These medications affect kidney function directly through GLP-1 receptors located in renal tissue and indirectly through weight loss and blood pressure reduction.

The pathway from dose to kidney effect runs through five connected steps.

1. Incretin mimicry. GLP-1 is a naturally occurring incretin hormone that the small intestine releases after meals. A review indexed on PubMed by the U.S. National Library of Medicine notes that GLP-1 stimulates insulin secretion and carries extra-pancreatic properties, including effects on kidney function. Slowed gastric emptying also prolongs fullness after eating, which supports reduced calorie intake.

2. Direct renal receptor binding. The kidney itself carries GLP-1 receptors. A Clinical Kidney Journal review reports that numerous human studies have shown GLP-1 receptors present in both the glomerulus and the renal tubule, and ClinicalTrials.gov records describe receptor expression in afferent arteriolar vascular smooth muscle cells, glomerular endothelial cells, macrophages, juxtaglomerular cells, and the proximal tubule. This distribution gives GLP-1 medications a biological pathway for renal effects independent of glucose lowering.

3. Natriuresis and pressure relief. The Clinical Kidney Journal review explains that GLP-1 receptor agonists counteract glomerular hyperfiltration by inducing diuresis and natriuresis through phosphorylation and inhibition of the sodium-hydrogen exchanger 3 in proximal tubular cells. A 2024 PubMed review adds that GLP-1 decreases activity and expression of SGLT1/2 in the tubules, which restores tubuloglomerular feedback and reduces intraglomerular pressure.

4. Indirect kidney protection. Weight loss and blood pressure reduction from GLP-1 weight-loss therapy lower mechanical stress on the kidneys by easing intraglomerular pressure. The Clinical Kidney Journal review links chronic GLP-1 receptor agonist intake with lower blood pressure, explained at least in part by the natriuretic mechanism.

GLP-1 receptor agonists come in injectable and oral formulations, and physician-supervised programs tailor the formulation and dose to each patient’s profile, including renal status. Dosing typically begins at a lower level and increases gradually as needed. The full GLP-1 drug reference guide documents the available formulations, dosing schedules, and class pharmacology.

Dual GIP/GLP-1 agonist therapy extends this mechanism class by adding glucose-dependent insulinotropic polypeptide (GIP) receptor activation to GLP-1 receptor activity. A review in Drugs (Springer Nature) acknowledges the class for efficacy in managing type 2 diabetes and obesity, with expanding cardiometabolic indications. A 2025 PubMed Central review reports mounting evidence that GLP-1 receptor agonist treatment can improve kidney function beyond merely lowering glucose levels in patients with diabetic kidney disease, and dual-agonist clinical programs now collect dedicated kidney outcome data within that expanding evidence base.

What did clinical trials, especially the FLOW trial, find about GLP-1 therapy and kidney disease progression?

The FLOW trial found that GLP-1 receptor agonist therapy reduced the risk of major kidney disease events by 24% in patients with type 2 diabetes and chronic kidney disease, according to a 2024 American Diabetes Association report. Researchers stopped the FLOW trial early after the kidney-protective benefit crossed the prespecified boundary for early termination.

The FLOW trial was the first study designed to assess the effect of a GLP-1 receptor agonist on primary composite kidney outcomes in patients with CKD and type 2 diabetes, according to a 2024 NephJC analysis. DelveInsight reports that the global randomized controlled trial began in 2019 and enrolled 3,533 participants across 387 sites in 28 countries. Per the Cleveland Clinic Journal of Medicine, enrollment required adults with type 2 diabetes already taking a renin-angiotensin system inhibitor, with an eGFR between 50 and 75 mL/min/1.73 m² and a urine albumin-to-creatinine ratio of 300 to 5,000 mg/g, or an eGFR between 25 and 50 with a ratio of 100 to 5,000 mg/g. That profile spans CKD stages 2 through 4, the population most likely to progress toward dialysis.

The FLOW trial measured kidney failure, a sustained eGFR decline of 50% or greater, and death from renal or cardiovascular causes as the composite primary endpoint. Kidney failure meant dialysis or transplantation. For patients, that endpoint counts the events people genuinely fear, not small shifts in a lab value.

Researchers followed participants for a median of 3.4 years before stopping the trial early due to evidence of benefit, according to DiabetesontheNet. The GLP-1 therapy arm produced a significant reduction in the primary composite renal endpoint compared with placebo, and the Cleveland Clinic Journal of Medicine reports a 24% reduction in the combined risk of major kidney outcomes, cardiovascular events, and death from any cause. GLP-1 receptor agonists demonstrated in these trials a clear slowing of eGFR decline in patients with type 2 diabetes and CKD. Early termination on efficacy grounds means the benefit was so pronounced that withholding the treatment from placebo participants became unethical. That threshold is rarely crossed in renal outcomes research, and generic summaries of the FLOW trial consistently omit this fact.

Earlier cardiovascular outcomes trials built the foundation for FLOW. LEADER, SUSTAIN-6, and REWIND were not designed as renal trials, yet each captured kidney secondary endpoints, and the SUSTAIN and SELECT cardiovascular findings extended that kidney data further. Because none of these trials were built to test renal outcomes, their consistent kidney signals function as unplanned independent replication, which strengthens confidence in the FLOW result.

Regulators and guideline committees have incorporated this evidence. FDA approval decisions for GLP-1 receptor agonists incorporated renal outcomes data, and American Diabetes Association guidelines now specifically recommend GLP-1 receptor agonists for patients with type 2 diabetes and chronic kidney disease.

What Renal Biomarkers Do Trials Use to Measure Kidney Health, and What Do They Show for GLP-1 Therapy?

Trials measure kidney health with two biomarkers: estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR). GLP-1 receptor agonist trials show slower eGFR decline and reduced UACR versus placebo, indicating preserved kidney function and less glomerular stress.

eGFR measures how well the kidneys filter waste from blood, and the eGFR slope describes how quickly that filtration rate declines over time. GLP-1 clinical trials use eGFR slope as a continuous measure of kidney function trajectory, because small year-to-year changes reveal protection long before kidney failure appears. Across these trials, GLP-1 receptor agonist therapy attenuated slope decline relative to placebo, meaning treated patients lost kidney function more slowly.

Urine albumin-to-creatinine ratio detects albumin leaking into urine, an early marker of glomerular damage. GLP-1 receptor agonist therapy reduced urine albumin-to-creatinine ratio in multiple trial populations, signaling less stress on the kidney’s filtering units even in patients without advanced disease.

Slope and composite endpoints answer different questions. Slope captures the ongoing rate of kidney function loss, while composite endpoints count discrete events such as dialysis, transplant, or renal death. A therapy can improve eGFR slope without yet reducing composite event rates, and vice versa, so patients should read both measures together rather than either one alone. The FLOW trial’s composite primary outcome was time to first occurrence of a persistent 50% or greater eGFR reduction, kidney failure, kidney death, or cardiovascular death, according to a 2024 Cleveland Clinic Journal of Medicine review.

eGFR staging (CKD stages 1 through 5) determines kidney disease severity and, for some GLP-1 agents, maximum recommended doses, which makes physician oversight throughout treatment genuinely important rather than optional.

Is GLP-1 therapy safe for patients who already have kidney problems?

Yes. Renal-outcomes trials enrolled patients with moderate-to-severe chronic kidney disease, and GLP-1 receptor agonists were generally well tolerated in that population. Gastrointestinal upset was the most common side effect, serious adverse events were rare, and kidney protection held across all CKD severity levels.

The safety evidence comes directly from CKD populations. Major renal-outcomes trials enrolled participants with baseline eGFR values as low as 25 mL/min/1.73m², which means the data reflects patients with advanced kidney impairment rather than healthy volunteers. According to a 2024 Cleveland Clinic Journal of Medicine review of the FLOW trial, GLP-1 receptor agonist therapy safely reduced the risk of major kidney outcomes regardless of CKD severity defined by baseline eGFR or UACR.

Gastrointestinal adverse events were the most common adverse events in GLP-1 renal trials, generally mild-to-moderate and transient. Nausea and vomiting accounted for most reports, and gastrointestinal-related discontinuation rates stayed low relative to the kidney-protective benefit observed. The GLP-1 therapy gastrointestinal side effects clinical data documents these tolerability patterns in detail.

Trial investigators attribute the kidney protection to mechanisms beyond blood glucose lowering, including reduced intraglomerular pressure and anti-inflammatory pathways. Because these mechanisms do not depend on diabetes status, the renal safety findings from CKD trial populations extend to patients whose primary goal is weight loss. Physician supervision remains part of that safety picture: baseline kidney function testing and periodic eGFR monitoring allow dosing to match each patient’s renal status.

What do these renal findings mean for patients considering a physician-supervised GLP-1 weight-loss program?

Renal findings mean that patients with chronic kidney disease can consider a physician-supervised GLP-1 weight-loss program with confidence. Kidney status informs dosing and monitoring frequency rather than automatic disqualification, and supervised programs include baseline and ongoing eGFR and UACR testing to protect renal health.

CKD comorbidity does not automatically exclude patients from physician-supervised GLP-1 weight-loss programs when managed with appropriate monitoring. Physician-supervised GLP-1 programs include ongoing renal function monitoring to detect early impairment and guide dosing decisions. Baseline estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) testing occurs before treatment begins, and repeat testing at scheduled intervals lets the care team adjust the plan early.

For patients living with both obesity and CKD, trial evidence suggests GLP-1 weight-loss therapy can address both conditions at once, a meaningful advantage over lifestyle intervention alone. Patients seeking GLP-1 therapy primarily for weight loss rather than diabetes can still gain kidney-protective benefit when early CKD or risk factors are present, and this remains an emerging research area beyond the diabetes-focused trial populations. The GLP-1 for diabetes vs weight loss how the goals differ explains how treatment intent shapes program design for each patient.

Dr. Cassandra B. Donnelly leads the medically supervised protocols at Age Well ATL, a practice offering physician-supervised medical weight loss Atlanta patients trust for individualized care. Dr. Donnelly earned her DO from Rowan University, completed an Emergency Medicine residency at Rutgers NJ Medical School, and has contributed to National Library of Medicine literature. With more than 30 years of clinical experience across emergency and osteopathic medicine, Dr. Donnelly evaluates every patient with renal comorbidities individually, because kidney health history deserves more than a checklist.

To find out whether a supervised GLP-1 program fits your kidney health profile, make an appointment with Age Well ATL by calling 404-287-0123.

Sources

• DelveInsight, "Semaglutide FLOW Trial Result | EASD 2024" (2024)
• Cleveland Clinic Journal of Medicine, "Semaglutide reduced the risk of major kidney outcomes in patients with type 2 diabetes and chronic kidney disease regardless of its severity: FLOW trial" (2024)
• DiabetesontheNet, "Diabetes Distilled: Keeping kidneys FLOWing – semaglutide improves renal outcomes" (2024)
• American Diabetes Association, "Semaglutide Reduced Risk for Major Kidney Disease Events by 24% for Patients with Type 2 Diabetes and Kidney Disease" (2024)